ECSP19031458A - PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOS - Google Patents
PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOSInfo
- Publication number
- ECSP19031458A ECSP19031458A ECSENADI201931458A ECDI201931458A ECSP19031458A EC SP19031458 A ECSP19031458 A EC SP19031458A EC SENADI201931458 A ECSENADI201931458 A EC SENADI201931458A EC DI201931458 A ECDI201931458 A EC DI201931458A EC SP19031458 A ECSP19031458 A EC SP19031458A
- Authority
- EC
- Ecuador
- Prior art keywords
- cartilage
- indoles
- treatment
- disorders
- pirido
- Prior art date
Links
- 210000000845 cartilage Anatomy 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000015100 cartilage disease Diseases 0.000 abstract 1
- 230000008421 cartilage matrix synthesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a 9H pirido[3,4-b]indoles sustituidos con 8-arilo y sustituidos con 8-heteroarilo de fórmula I, en la que A, E, G, R1 a R6 y R10 son como se definen en las reivindicaciones, que estimulan la condrogénesis y la síntesis de la matriz del cartílago y se pueden usar en el tratamiento de trastornos y afecciones del cartílago en los que se desea la regeneración del cartílago dañado, por ejemplo, enfermedades de las articulaciones tales como la osteoartritis. La invención se refiere además a procedimientos para la síntesis de los compuestos de fórmula I, su uso como productos farmacéuticos, y a composiciones farmacéuticas que los comprenden.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (en) | 2016-11-07 | 2016-11-07 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19031458A true ECSP19031458A (es) | 2019-05-31 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201931458A ECSP19031458A (es) | 2016-11-07 | 2019-05-06 | PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOS |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11130755B2 (es) |
| EP (3) | EP3318563A1 (es) |
| JP (1) | JP7046063B2 (es) |
| KR (1) | KR102490199B1 (es) |
| CN (1) | CN110382496B (es) |
| AR (1) | AR110136A1 (es) |
| AU (2) | AU2017353381B2 (es) |
| CA (1) | CA3042332A1 (es) |
| CL (1) | CL2019001251A1 (es) |
| CO (1) | CO2019005090A2 (es) |
| CR (1) | CR20190217A (es) |
| DK (1) | DK3535263T3 (es) |
| DO (1) | DOP2019000112A (es) |
| EA (1) | EA038365B1 (es) |
| EC (1) | ECSP19031458A (es) |
| ES (1) | ES2837765T3 (es) |
| HR (1) | HRP20201754T1 (es) |
| HU (1) | HUE052187T2 (es) |
| IL (1) | IL265982B (es) |
| LT (1) | LT3535263T (es) |
| MA (1) | MA45803B1 (es) |
| MX (1) | MX383580B (es) |
| MY (1) | MY189589A (es) |
| PE (1) | PE20191032A1 (es) |
| PH (1) | PH12019500997B1 (es) |
| PT (1) | PT3535263T (es) |
| RS (1) | RS61172B1 (es) |
| SG (1) | SG11201903195YA (es) |
| SI (1) | SI3535263T1 (es) |
| TN (1) | TN2019000143A1 (es) |
| TW (1) | TWI753966B (es) |
| UY (1) | UY37473A (es) |
| WO (1) | WO2018083157A1 (es) |
| ZA (1) | ZA201902111B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN111936490A (zh) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| EP3768267B1 (en) * | 2018-03-20 | 2025-05-14 | Icahn School of Medicine at Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| KR20220044721A (ko) * | 2019-08-06 | 2022-04-11 | 도메인 테라퓨틱스 | 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물 |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) * | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| JP4599501B2 (ja) | 2001-11-07 | 2010-12-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 多発性骨髄腫および他の癌の処置におけるＩκＢのインヒビターとしてのカルボリン誘導体 |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| WO2006013739A1 (ja) | 2004-08-04 | 2006-02-09 | Konica Minolta Holdings, Inc. | 有機エレクトロルミネッセンス素子、照明装置及び表示装置 |
| CA2658511C (en) | 2006-08-25 | 2019-02-19 | Ares Trading S.A. | Use of fgf-18 compound to treat cartilage disorders |
| WO2008132454A1 (en) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| FR2916380B1 (fr) * | 2007-05-21 | 2009-07-31 | Saint Gobain | Procede et dispositif de surmoulage d'un element vitre par une portion de joint comportant un insert, vitrage et insert notamment pour ce procede. |
| WO2010038153A1 (en) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Use of sox transcription factor acti\ators for stimulating chondrogenesis |
| US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2455378A1 (en) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/en not_active Withdrawn
-
2017
- 2017-11-02 HR HRP20201754TT patent/HRP20201754T1/hr unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/en not_active Ceased
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 CA CA3042332A patent/CA3042332A1/en active Pending
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/en active Pending
- 2017-11-02 PH PH1/2019/500997A patent/PH12019500997B1/en unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active Active
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/en active Active
- 2017-11-02 MX MX2019005308A patent/MX383580B/es unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es active IP Right Grant
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US12275733B2/en active Active
-
2025
- 2025-03-03 US US19/068,406 patent/US20250333412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19031458A (es) | PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOS | |
| UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
| MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| PA8814301A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| UY36126A (es) | ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?. | |
| CR20200484A (es) | COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574) | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| MX2017000926A (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble. | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CO2017000443A2 (es) | Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa | |
| CR20170247A (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| CO2021007402A2 (es) | Constructos de suministro para transcitosis y métodos relacionados | |
| MX2020001157A (es) | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). | |
| BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida | |
| MX2019011265A (es) | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. |